TL;DR
- 1.Sermorelin is the only GHRH analog with a prior FDA approval history -- making it the only one with an active 503A compounding pathway as CJC-1295 faces mounting regulatory pressure in 2026.
- 2.Start at 200-350 mcg subcutaneous before bed (dose by body weight below). Recheck IGF-1 at 4-6 weeks and titrate in 50 mcg increments to hit 180-260 ng/mL.
- 3.A 2026 meta-analysis in Obesity Research and Clinical Practice confirmed a 1.42 kg lean mass gain across five GHRH analog RCTs -- but only in participants who trained at least three times weekly.
- 4.Use a 5-nights-on, 2-nights-off schedule. Daily dosing for more than 6-8 continuous weeks starts compressing the GH pulse. Cycle off for 4-8 weeks after 6 months.
- 5.Body weight explains only about 15-20% of your IGF-1 response variance. The rest is your GHRHR and GHR genotype. The weight-based chart gets you started. Your 6-week bloodwork tells you where to land.
Most sermorelin dosage guides give you a flat "200-500 mcg nightly" range and call it done. That range is not wrong. But the 72-week study that produced the most dramatic results -- 2.1 kg of lean mass and 6.3% visceral fat reduction -- did not use a flat range. It used dose titration at week 6 based on IGF-1 response, and every participant was resistance training three times weekly. Without those two variables, lean mass gain from GHRH therapy in the clinical literature drops to statistical noise. The dose alone is not the protocol.
Sermorelin has more human clinical data than any other compoundable GHRH analog, backed by FDA review history dating to its 1997 approval as Geref. No other GHRH peptide currently accessible through 503A compounding has that history.
Sermorelin is GHRH 1-29, a synthetic 29-amino-acid fragment of growth hormone releasing hormone. It binds the GHRH receptor on your pituitary and triggers a GH pulse -- the same signal your hypothalamus sends naturally, just delivered externally on a schedule. Unlike synthetic HGH, which floods your system with a constant, non-pulsatile GH level, sermorelin preserves the pulsatile pattern that your IGF-1 axis is built around. This makes it the most physiologically conservative GHRH option and the one that causes the fewest problems with long-term receptor sensitivity.
In 2024-2026, as FDA scrutiny on CJC-1295 increased and compounding pharmacy access to that peptide narrowed, sermorelin became the default GHRH analog for 503A clinics. If you are considering GHRH therapy in 2026, this is where most protocols begin.
Think of sermorelin as a scheduled alarm that rings your pituitary at bedtime. The pituitary releases GH for a short burst, then the signal disappears within hours. CJC-1295 with Drug Affinity Complex is more like leaving the alarm on continuously for 7-10 days. Sermorelin works with your body's existing rhythm. CJC-1295 overrides it. Both increase IGF-1, but the receptor implications over months of use are very different.
What Sermorelin Actually Does: The Results From 20 Years of Trials
Adults with low-normal IGF-1 (baseline below 150 ng/mL) see IGF-1 increases of 40-80% within the first 4-6 weeks of a standard sermorelin protocol. In participants who were already in the normal range, the increase is more modest: 20-40%. A 2026 meta-analysis by Badran and Helal in Obesity Research and Clinical Practice pooled five randomized controlled trials of GHRH analogs and confirmed a mean 1.42 kg increase in lean mass across all participants. The subgroup that combined peptide therapy with resistance training showed significantly larger lean mass gains.
"GHRH analog therapy produced meaningful lean mass gains only in participants who maintained structured resistance exercise. The peptide amplifies the anabolic signal from training -- it does not create lean mass in the absence of that stimulus."
Badran and Helal, Obesity Research and Clinical Practice, 2026 meta-analysis of five GHRH analog RCTs
A 2025 review in the Journal of Stem Cell Research identified sermorelin as the lowest-risk entry point in the GHRH peptide class for healthy adults seeking anabolic and regenerative effects. The reviewers noted strong data on soft tissue repair and recovery alongside meaningful body composition effects, while flagging the absence of large-scale RCTs specific to sermorelin (as opposed to GHRH analogs generally) as the primary evidence gap compared to tesamorelin, the only FDA-approved GHRH peptide.
The "well, actually" moment most guides skip over: studies on GHRH analogs that did not require participants to train produced near-zero lean mass benefit on average. The peptide is an amplifier. It amplifies whatever anabolic signal already exists from your training. If that signal is absent, there is nothing to amplify. Sermorelin without consistent training is paying for a gym membership and never going.
Week-by-Week Timeline: What You Will Actually Feel
IGF-1 elevations show up in blood tests before they show up in the mirror. Here is a realistic timeline based on the clinical data and what users consistently report.
| Timeframe | What Changes | What to Track |
|---|---|---|
| Week 1-2 | Sleep depth improves, vivid dreams return, morning energy increases | Sleep quality, morning mood |
| Week 3-4 | Recovery between training sessions accelerates, less delayed soreness | Soreness duration, training performance |
| Week 5-6 | IGF-1 reaches new baseline (draw morning fasted labs now) | IGF-1 blood test, titrate dose based on result |
| Week 8-12 | Visible lean mass and body composition changes begin | Waist circumference, body fat percentage |
| Month 4-6 | Full lean mass benefit accumulates (1.42 kg average per meta-analysis) | DEXA scan if available, re-check IGF-1 |
| Month 6 | Cycle off for 4-8 weeks to allow receptor resensitization | Allow natural GH axis to recalibrate before next cycle |
Sermorelin Dosage Chart by Body Weight: Where to Start
Body weight determines your starting dose. It does not determine your final dose. The 6-week IGF-1 test is what does that. Use the chart below as your week-1 baseline, then titrate based on where your IGF-1 lands.
| Body Weight | Starting Dose | After 6-Week IGF-1 Test | Max Dose |
|---|---|---|---|
| Under 70 kg (154 lbs) | 200 mcg/night | Hold at 200 if IGF-1 is 180-260; add 50 mcg if below 180 | 350 mcg |
| 70-90 kg (154-198 lbs) | 250 mcg/night | Hold at 250 if IGF-1 is 180-260; add 50 mcg if below 180 | 400 mcg |
| 90-110 kg (198-242 lbs) | 300 mcg/night | Hold at 300 if IGF-1 is 180-260; add 50 mcg if below 180 | 500 mcg |
| Over 110 kg (242+ lbs) | 350 mcg/night | Hold at 350 if IGF-1 is 180-260; add 50 mcg if below 180 | 500 mcg |
Timing rule: Subcutaneous injection 30-60 minutes before bed. Sleep is when your natural GH pulse is largest. Sermorelin amplifies this pulse, not a daytime one. Eating within 2 hours before injection triggers somatostatin release that blunts GH output significantly. Fast for at least 2 hours before your dose.
Frequency rule: 5 nights on, 2 nights off. Clinical protocols use this schedule specifically to prevent receptor downregulation. Daily dosing for 6-8 weeks straight begins compressing the GH pulse magnitude as GHRH receptors gradually desensitize. The two off-nights per week allow partial resensitization and maintain the effectiveness of each dose through the full 6-month cycle. For the full receptor biology behind this, see our article on how long GH receptors take to reset after a peptide cycle.
Standard Protocol (Body Composition)
- Dose: 200-500 mcg subcutaneous, weight-based
- Timing: 30-60 minutes before bed, 2-hour food fast
- Frequency: 5 nights on, 2 nights off
- Cycle length: 6 months on, 4-8 weeks off
- First IGF-1 draw: 4-6 weeks in (morning, fasted)
- Target IGF-1: 180-260 ng/mL (age-adjusted)
Maintenance Protocol (Anti-Aging)
- Dose: 100-200 mcg subcutaneous, weight-based
- Timing: 30-60 minutes before bed, 2-hour food fast
- Frequency: 5 nights on, 2 nights off (or 3 on, 4 off)
- Cycle length: Year-round at lower doses with quarterly IGF-1 monitoring
- Target IGF-1: Age-appropriate low-normal range
- Re-evaluate: Every 3 months
Why Sermorelin Is Legal and CJC-1295 Is Increasingly Not
Most people searching for sermorelin dosage are really asking a second question: is sermorelin actually worth switching to from CJC-1295?
Sermorelin was FDA-approved as Geref in 1997 for diagnosing GH deficiency in children. The commercial product was withdrawn in 2008, not for safety reasons, but because synthetic HGH had taken over the market. That approval history gives sermorelin something no newer GHRH analog can claim: an established safety review record at the agency level. When the FDA evaluates whether a peptide is appropriate for 503A compounding, prior approval is a significant factor.
CJC-1295 was never FDA-approved. In late 2024, an FDA advisory committee review increased scrutiny on novel peptides that lacked prior approval history. CJC-1295, particularly the Drug Affinity Complex (DAC) version with its 7-10 day half-life, came under significantly more pressure under 503B outsourcing facility rules. Most major 503A compounding pharmacies pivoted their GHRH analog business to sermorelin as a result. For a full comparison of how sermorelin sits against other GH peptides on regulatory and evidence grounds, see the tesamorelin vs MK-677 vs CJC-1295 comparison.
The practical consequence in 2026: a January FDA guidance introduced prescriber attestation requirements before 503B facilities will compound sermorelin, which pushed standard 3 mg vial prices to $220-$310 (up from $180-$240 in late 2025). Sermorelin got more expensive. It did not get inaccessible. That distinction matters if you are planning a 6-month cycle. The comparison with ipamorelin vs CJC-1295 is worth reading to understand the full picture of what changed in the GH peptide compounding landscape and why.
Average lean mass increase across five randomized controlled trials of GHRH analogs, per the 2026 Badran and Helal meta-analysis. The effect was significantly larger in the subgroup that maintained resistance training at least three times weekly throughout the study period.
How Long Should You Run Sermorelin Before Cycling Off?
The standard answer is 6 months on, 4-8 weeks off. The receptor biology is the reason.
Sermorelin's short half-life means it does not continuously stimulate pituitary GHRH receptors the way CJC-1295 with DAC does. The 5-on/2-off weekly schedule already provides partial receptor recovery. A full 6-month cycle at this frequency tends not to produce significant desensitization if the weekly schedule is respected. Injectable GHRPs like hexarelin or GHRP-2 desensitize within 7-14 days of daily dosing. Sermorelin on the 5/2 schedule is far more forgiving.
The signal to watch is not time but IGF-1 trend. If your IGF-1 was stable at 220 ng/mL through week 12 and drops to 170 ng/mL by week 18 on the same dose, that is a receptor sensitivity signal. In that case, reduce frequency to 3 nights per week for 4-6 weeks before cycling off completely, rather than pushing dose higher to compensate. Higher dose into a desensitized receptor does not recover the signal -- it deepens the problem.
What Your GHRHR Gene Tells You About Your Dose Before You Start
Body weight sets your starting dose. Your GHRHR gene determines where you actually end up -- sometimes by a factor of 2-3.
GHRHR is the pituitary receptor sermorelin binds to trigger GH release. Variants in GHRHR that reduce receptor expression mean sermorelin has fewer binding sites per dose. Users with reduced GHRHR expression often plateau at lower IGF-1 levels despite dose increases. This is a genetic ceiling, not a protocol failure. Knowing your genotype before you start means you set realistic targets instead of chasing a number your biology cannot reach.
On the amplification side, the GHR exon 3 deletion (d3) variant doubles the downstream IGF-1 response from the same GH pulse. d3 homozygotes frequently hit the top of the 180-260 ng/mL target range at 200 mcg alone. Pushing to 400 mcg in this group can overshoot the target range without obvious warning signs until bloodwork. The full explanation of this variant and its clinical implications is in our article on GHR exon 3 deletion and peptide response.
One more thing worth knowing: sermorelin is cleared by serum proteases, not by CYP enzymes. CYP2D6 slow metabolizer status changes how you process many drugs -- but it has zero effect on sermorelin clearance. This is different from synthetic peptides that go through hepatic metabolism. Your drug metabolism genetics are irrelevant to this particular peptide.
If you want to know your GHRHR and GHR genotype before committing to a 6-month cycle, a full sermorelin genetic match from your DNA data will tell you where your ceiling is and what starting dose your profile actually calls for.
Verdict
Sermorelin is the most documented GHRH analog still accessible through compounding in 2026, with a regulatory position that CJC-1295 increasingly cannot match. The weight-based dosing chart gets you started. The 6-week IGF-1 test tells you where your genetics actually put your ceiling. The training requirement is not optional: the studies showing 1.42-2.1 kg lean mass gains all required structured resistance exercise.
To know which GHRH protocol your genotype supports before spending six months guessing on dose, upload your genetic data for a matched peptide report, or order a saliva kit and we will run the full panel for you.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
How long does sermorelin take to work?
Sleep quality and morning energy typically improve within 1-2 weeks, as GH has a direct effect on slow-wave sleep architecture. Recovery between training sessions accelerates by week 3-4. Visible body composition changes take 8-12 weeks. The full lean mass benefit documented in the clinical literature (averaging 1.42 kg in a 2026 meta-analysis) accumulates over 4-6 months of consistent use with resistance training.
What is the best time of day to take sermorelin?
30-60 minutes before bed, with at least a 2-hour food fast beforehand. Your natural GH pulse is largest during the first few hours of sleep. Sermorelin amplifies this pulse rather than creating a new one at an arbitrary time. Eating within 2 hours before dosing triggers somatostatin release that significantly blunts GH output per injection.
Can you take sermorelin every day?
Clinical protocols use a 5-nights-on, 2-nights-off schedule rather than daily dosing. Continuous daily use for 6-8 weeks starts compressing the GH pulse magnitude as GHRH receptors gradually desensitize. The two weekly off-nights allow partial receptor resensitization and maintain the effectiveness of each dose across a full 6-month cycle. Daily dosing is not dangerous, but it reduces the return on each injection.
Does sermorelin spike cortisol like GHRP-2?
No. Sermorelin is a GHRH analog, not a GHRP, and does not act on the ghrelin receptor (GHSR) where cortisol and ACTH co-stimulation in GHRPs originates. At clinical doses, sermorelin produces a selective GH pulse without meaningful ACTH or cortisol elevation. This makes it fundamentally different from GHRP-2 or hexarelin in terms of adrenal axis impact.
What should my IGF-1 be on sermorelin?
The standard clinical target is 180-260 ng/mL, adjusted for age. Adults over 60 generally target the lower end (around 180-200 ng/mL). Below 180 ng/mL at your 6-week test suggests a 50 mcg dose increase is warranted. Above 300 ng/mL suggests reducing dose or extending your weekly off-days before the next adjustment. Test in the morning, fasted, for a consistent baseline.
Can you stack sermorelin with ipamorelin?
Yes. Sermorelin (a GHRH analog) and ipamorelin (a GHRP) act on completely different receptors and produce a synergistic GH pulse when combined. The standard combination is 200-300 mcg sermorelin plus 200-300 mcg ipamorelin, both administered 30-60 minutes before bed. This combination became more popular as the CJC-1295 plus ipamorelin stack became harder to access through compounding.
Is sermorelin legal in the US in 2026?
Yes, with a prescription from a licensed physician. Sermorelin is not a scheduled substance and is available through 503A compounding pharmacies. A January 2026 FDA guidance introduced prescriber attestation requirements that added a documentation step for clinics, which pushed prices up 20-35% in early 2026. But the 503A pathway remains intact. CJC-1295 is in a more precarious position, which is why most clinics now default to sermorelin for GHRH therapy.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.